| Literature DB >> 31662976 |
Congcong Xu1, Zhen Xu1, Caixiu Lin2, Sheng Feng3, Mingwei Sun4, Jijun Chen4, Yichun Zheng1.
Abstract
BACKGROUND: Holmium laser enucleation of the prostate (HoLEP) is considered the standard endoscopic treatment of benign prostatic hyperplasia (BPH), but traditional HoLEP surgery will cause some postoperative complications. This study was attempted to evaluate the safety and efficacy of modified two-lobe technique versus traditional three-lobe technique of HoLEP focusing mainly on incidences of retrograde ejaculation (RE) and urinary incontinence (UI).Entities:
Mesh:
Year: 2019 PMID: 31662976 PMCID: PMC6791212 DOI: 10.1155/2019/3875418
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Flow of participants through the study.
Figure 2Surgical procedures of modified two-lobe technique. (a) Step 1: incision is made circumferentially from the 7 o'clock position to the 11 o'clock position near the verumontanum. (a, b) Step 2: incision is lengthened down to 11 o'clock, approximately 1 cm from the bladder neck. (b) Step 3: Incision is made laterally to the 7 o'clock position near the bladder neck. (a, b) Step 4: incision is made back to the starting point. (c) Bladder neck after the unilateral lobe has been released. (d) Step 5: incision is made circumferentially from the 7 o'clock position to the 1 o'clock position near the verumontanum. (d, e) Step 6: incision is lengthened down to 1 o'clock, approximately 1 cm from the bladder neck. (e) Step 7: incision is made back to the 7 o'clock near the verumontanum. (f) Bladder neck after three lobes has been released. (g) The mucous membranes of the prostatic urethra from the 11 o'clock to 1 o'clock positions are preserved.
Preoperative patients' characteristics.
| Variables | Modified HoLEP | Traditional HoLEP |
|
|---|---|---|---|
| Age (yr) | 70.3 ± 7.1 | 71.9 ± 8.0 | 0.145 |
| Prostate volume (cc) | 71.3 ± 10.9 | 72.0 ± 11.1 | 0.661 |
| PSA (ng/ml) | 3.2 ± 1.51 | 3.3 ± 1.50 | 0.647 |
| PVR (ml) | 126.2 ± 101.9 | 139.9 ± 70.8 | 0.283 |
|
| 7.0 ± 0.87 | 6.9 ± 0.91 | 0.438 |
| IPSS | 22.6 ± 2.02 | 22.2 ± 2.11 | 0.182 |
| QoL score | 4.7 ± 1.09 | 4.6 ± 1.07 | 0.523 |
| Indwelling catheter | 7.2% (7/97) | 7.4% (7/94) | 0.951‡ |
| IIEF | |||
| Erectile function | 13.4 ± 6.7 | 13.0 ± 6.7 | 0.832 |
| Orgasmic function | 6.6 ± 3.6 | 5.5 ± 2.7 | 0.233 |
| Intercourse satisfaction | 4.9 ± 2.7 | 6.8 ± 4.4 | 0.060 |
| Overall satisfaction | 5.5 ± 3.7 | 4.6 ± 5.2 | 0.469 |
HoLEP = holmium laser enucleation of the prostate; PSA = prostate-specific antigen; PVR = postvoid residual urine volume; Qmax = maximum flow rate; IPSS = International Prostate Symptom Score; QoL = quality of life; IIEF = International Index of Erectile Function; t-test; ‡Pearson's chi-square test.
Perioperative data.
| Variables | Modified HoLEP | Traditional HoLEP |
|
|---|---|---|---|
| Operative time (min) | 72.1 ± 20.3 | 70.1 ± 22.7 | 0.521 |
| Enucleation time (min) | 50.1 ± 15.1 | 49.2 ± 13.9 | 0.669 |
| Morcellation time (min) | 15.6 ± 8.8 | 15.2 ± 8.3 | 0.747 |
| Transfusion rate, % | 0 | 0 | |
| Hospitalization (days) | 3.5 ± 1.22 | 3.6 ± 1.47 | 0.609 |
| Catheterization (days) | 2.7 ± 0.6 | 2.8 ± 0.8 | 0.329 |
| HGB levels drop (g/dl) | 1.7 ± 1.1 | 1.9 ± 1.4 | 0.273 |
t-test.
Patient outcome scores over time.
| Follow-up | 1 month | 3 months | 6 months | 12 months |
|---|---|---|---|---|
| No. of patients | ||||
| Modified | 97 | 93 | 89 | 84 |
| Traditional | 94 | 91 | 86 | 82 |
| PVR change (ml) | ||||
| Modified | −86.0 ± 57.1 | −92.4 ± 55.0 | −93.3 ± 49.6 | −97.1 ± 58.5 |
| Traditional | −102.0 ± 55.9 | −107.9 ± 56.2 | −108.6 ± 60.2 | −111.4 ± 42.6 |
| | 0.052 | 0.060 | 0.068 | 0.074 |
| IPSS score change | ||||
| Modified | −13.8 ± 3.07 | −15.8 ± 3.56 | −16.3 ± 2.76 | −16.6 ± 2.10 |
| Traditional | −13.7 ± 3.41 | −16.0 ± 3.29 | −16.4 ± 2.51 | −16.8 ± 2.83 |
| | 0.831 | 0.693 | 0.803 | 0.605 |
| QoL score change | ||||
| Modified | −2.2 ± 0.99 | −3.1 ± 0.63 | −3.2 ± 0.58 | −3.4 ± 0.52 |
| Traditional | −1.8 ± 0.76 | −2.8 ± 0.77 | −3.0 ± 0.60 | −3.2 ± 0.53 |
| | 0.002 | 0.004 | 0.026 | 0.015 |
|
| ||||
| Modified | +15.3 ± 2.43 | +16.6 ± 2.88 | +17.4 ± 3.19 | +17.3 ± 3.28 |
| Traditional | +16.7 ± 4.12 | +17.4 ± 3.71 | +18.4 ± 4.23 | +18.1 ± 3.16 |
| | 0.005 | 0.428 | 0.079 | 0.163 |
| IIFF score change | ||||
| Modified | −1.3 ± 0.8 | +0.8 ± 0.4 | ||
| Traditional | −1.4 ± 0.9 | +0.7 ± 0.4 | ||
| | 0.146 | 0.109 |
PVR = postvoid residual urine volume; IPSS = International Prostate Symptom Score; QoL = quality of life; Qmax = maximum flow rate; IIEF = International Index of Erectile Function; t-test.
Incidence of late complications.
| Complication | Modified | Traditional |
|
|---|---|---|---|
| Early postoperative complications | |||
| Transient urinary incontinence | 1.03% (1/97) | 8.51% (8/94) | 0.036† |
| Acute urinary retention | 1.03% (1/97) | 0 | 1.000† |
| Late postoperative complications | |||
| 6-month postoperative retrograde ejaculation | 33.33% (10/30) | 63.64% (14/22) | 0.030‡ |
| 6-month postoperative ejaculatory volume (ml) | 1.5 ± 1.0 | 1.0 ± 0.7 | 0.050 |
| 12-month postoperative urinary incontinence | 0 (0/84) | 2.38% (2/82) | 0.242§ |
| 12-month postoperative urethral stricture | 3.57% (3/84) | 1.21% (1/82) | 0.630† |
| 12-month postoperative retrograde ejaculation | 13.33% (4/30) | 50% (11/22) | 0.034‡ |
| 12-month postoperative ejaculatory volume (ml) | 1.8 ± 0.6 | 1.2 ± 0.8 | 0.003 |
| 12-month postoperative re-TURP | 0 (0/84) | 0 (0/82) | — |
BPH = benign prostatic hyperplasia; TURP = transurethral resection of the prostate; †continuity correction chi-square test; ‡Pearson's chi-square test; §Fisher's exact test; t-test.